Last reviewed · How we verify
NCT03669120
Tailored Smoking Cessation Intervention in Promoting Sexual and Gender Minority Smokers to Quit Smoking
NA trial testing Informational Intervention in Cigarette Smoker in 46 participants. Completed in 25 March 2020.
25 March 2020
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 46 |
| Start date | 10 August 2018 |
| Primary completion | 25 March 2020 |
| Estimated completion | 25 March 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Informational Intervention
- Telephone-Based Intervention
Conditions studied
- Cigarette Smoker — all drugs for Cigarette Smoker →
- Current Every Day Smoker — all drugs for Current Every Day Smoker →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
Eligibility, any sex, with Cigarette Smoker or Current Every Day Smoker. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial studies how well tailored smoking cessation intervention works in promoting sexual and gender minority smokers to quit smoking. A program that is specifically designed for the lesbian, gay, bisexual, and transgender community may affect these participants differently than a traditional approach.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03669120
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Informational Intervention
Trials testing the same drug.
- NCT06977503 — Electrotherapy Stimulation Together With Life Coaching for the Support of Burnout Symptoms in Healthcare Workers · NA · recruiting
- NCT07455513 — A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer · NA · not yet recruiting
- NCT06927947 — Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes · NA · recruiting
- NCT06568016 — A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemi · NA · recruiting
- NCT06639958 — A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home · NA · suspended
Other recruiting trials for Cigarette Smoker
Currently open trials in the same condition.
- NCT03865472 — rTMS in Promoting Smoking Cessation and Preventing Relapse in Current Smokers · NA · active not recruiting
- NCT03199651 — Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer · NA · recruiting
- NCT02697227 — Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation · NA · active not recruiting
- NCT02271919 — Varenicline and Combined NRT for Smoking Cessation · Phase 4 · active not recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03669120 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 2 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03669120.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing